Skip to main content

Table 1 Demographic, clinical, histological, molecular and treatment characteristics of all patients (n = 400) and analysis of groups homogeneity (Pearson Chi2-test)

From: Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution

Characteristics Group A [n = 249] No (%) Group B [n = 151] No (%) P value
Age
   < 40 76 (30.5%) 25 (16.6%) 0.001
   ≥ 40 173 (69.5%) 122 (83.4%)  
Menopausal status
   No 178 (71.5%) 85 (56.3%) 0.008
   Yes 60 (24.1%) 56 (37.1%)  
   Unknown 11 (4.4%) 10 (6.6%)  
Side
   Right 128 (51.4%) 72 (47.7%) 0.552
   Left 120 (48.2%) 79 (52.2%)  
   Bilateral 1 (0.4%) 0  
Surgery
   Mastectomy 209 (83.9%) 130 (86.1%) 0.561
   BCT 40 (16.1%) 21 (13.9%)  
Histology
   DIC 231 (92.8%) 136 (90.1%) 0.248
   LIC 12 (4.8%) 13 (8.6%)  
   Other 1 0  
   Unknown 5 (2%) 2 (1.3%)  
SBR
   I 15 (6%) 12 (7.9%) 0.72
   II 153 (61.4%) 97 (64.2%)  
   III 74 (29.7%) 38 (25.2%)  
   Unknown 7 (2.8%) 4 (2.6%)  
Hormonal Receptor
   ER+/PR+ 123 (49.4%) 84 (55.6%) 0.205
   ER+/PR- 31 (12.4%) 25 (16.6%)  
   ER-/PR+ 25 (10%) 12 (7.9%)  
   ER-/PR- 65 (26.1%) 28 (18.5%)  
   Unknown 5 (2%) 2 (1.3%)  
Tumour
   pT1 28 (11.2%) 21 (13.9%) 0.867
   pT2 142 (57%) 84 (55.6%)  
   pT3 63 (25.3%) 35 (23.2%)  
   pT4 12 (4.8%) 7 (4.6%)  
   Unknown 4 (1.6%) 4 (2.6%)  
pN, axillary
   pN0 44 (17.7%) 42 (27.8%) 0.009
   pN1 69 (27.7%) 46 (30.5%)  
   pN2 77 (30.9%) 47 (31.1%)  
   pN3 50 (20.1%) 13 (8.6%)  
   Unknown 9 (3.6%) 3 (2%)  
Number of cycle of CT delivered with RT
   1 87 (34.9%) 25 (16.6%) < 0.001
   ≥ 2 162 (65.1%) 126 (83.4%)  
Breast/thoracic wall irradiation
   No 2 (0.8%) 12 (7.9%) < 0.001
   Yes 247 (99.2%) 139 (92.1%)  
Prophylactic supraclavicular fossa radiotherapy
   No 17 (6.8%) 10 (6.6%) 0.556
   Yes 232 (93.2%) 141 (93.4%)  
Internal mammary radiotherapy
   No 16 (6.4%) 9 (6%) 0.517
   Yes 233 (93.6%) 142 (94%)  
Axillary radiotherapy
   No 220 (88.4%) 120 (79.5%) 0.012
   Yes 29 (11.6%) 31 (20.5%)  
  1. Abbreviations: BCT = breast conservative therapy; SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor